Scarica l'app Stockscreener
446.00
2.29%
10.00
Dopo l'orario di chiusura:
446.25
0.25
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Vertex Pharmaceuticals’ SWOT analysis: cystic fibrosis leader faces diversification challenges - Investing.com
Vertex divulges new Nav1.8 blockers for pain - BioWorld MedTech
2 Monster Growth Stocks to Buy and Hold for 10 Years - The Motley Fool
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? (NASDAQ:VRTX) - Seeking Alpha
Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Downgraded Due to High Inventory Levels | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $4 Billion Share Buyback Program - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Yahoo Finance
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga
Vertex Pharma stock gains on share buybacks (VRTX:NASDAQ) - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Rep - GuruFocus
Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases - marketscreener.com
August 15th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss - Yahoo Finance
Vertex to Participate in Upcoming Investor Conferences | VRTX Stock News - GuruFocus
Vertex to Participate in Upcoming Investor Conferences - Business Wire
Vertex Pharmaceuticals Holds Annual Shareholder Meeting - TipRanks
Stifel maintains hold on Vertex stock with $494 target - Investing.com
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Best Biotech Stocks to Buy in 2025 - MarketBeat
Fund Update: TRILLIUM ASSET MANAGEMENT, LLC added 38,854 shares of VERTEX PHARMACEUTICALS ($VRTX) to their portfolio - Nasdaq
Our future journey in cystic fibrosis - Vertex Pharmaceuticals
Vertex says late-stage studies of VX-659 triple combination therapy in CF hit main goals - FirstWord Pharma
ViewPoints: Vertex settles on a dynastic successor - FirstWord Pharma
Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF - FirstWord Pharma
Vertex moves forward with regulatory filings after selecting VX-445 for triple-combination regimen in CF - FirstWord Pharma
Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - MSN
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Insider Monkey
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN
Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq
Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus
Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha
Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com
Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq
Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com
5.62%
2.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):